• Musculoskeletal ambulation disability symptom complex as a risk factor of incident bone fragility fr...

• Yoshii Ichiro

• Chijiwa Tatsumi, Sawada Naoya, Kokei Shohei

• Osteoporosis and Sarcopenia   2021  Volume.7  No.3 115 ~ 120

• Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6...

• Mochizuki Takeshi

• Yano Koichiro, Ikari Katsunori, Okazaki Ken

• Osteoporosis and Sarcopenia   2021  Volume.7  No.3 110 ~ 114

• Osteoporosis treatment rates after hip fracture 2011?2019 in Hawaii: Undertreatment of men after hip...

• Taylor Luke

• Kimata Chieko, Siu Andrea M., Andrews Samantha N., Purohit Prashant, Yamauchi Melissa, Bratincs...

• Osteoporosis and Sarcopenia   2021  Volume.7  No.3 103 ~ 109

• Intervention thresholds to identify postmenopausal women with high fracture risk: A single center st...

• Li-Yu Julie

• Lekamwasam Sarath

• Osteoporosis and Sarcopenia   2021  Volume.7  No.3 98 ~ 102

• Prevalence of osteoporosis in elderly women in Hong Kong

• Lo Sue Seen-Tsing

• Osteoporosis and Sarcopenia   2021  Volume.7  No.3 92 ~ 97

• Romosozumab and cardiovascular safety in Japan

• Takeuchi Yasuhiro

• Osteoporosis and Sarcopenia   2021  Volume.7  No.3 89 ~ 91